Eli Lilly & Co. (LLY)
$36.59
0.47 (+1.30%)
| CAPS Rating |
|
|---|---|
| Open | $36.04 |
| Previous Close | $36.12 |
| Daily Range | $36.00 - $36.70 |
| 52-Week Range | $27.21 - $40.78 |
| Market Cap | $42.04B |
| P/E Ratio | 17.77 |
| Dividend (Yield) | 1.96 (5.40%) |
| Volume | 7,320,045 |
| Average Daily Volume | 7,278,000 |
LLY
VS S&P 500 (SPY)
How do you think LLY will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
LLY Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
LLY News and Commentary
- This Baby Is a Nice Addition – The Motley Fool
- 5 Signs of a Strong Dividend Stock – The Motley Fool
- CORRECT:Justice Dept's Health-Care Fraud Caseload Nears 1,000 – SmartMoney
- US Justice Dept: Health-Care Fraud Caseload Grows – SmartMoney
- Another Paradigm Change for Pharma – Blog at The Motley Fool
- Eli Lilly To Pay $2 Million Cash Severance To Retiring R&D Chief – SmartMoney
- Your Heart or Your Stomach? – The Motley Fool
- VIVUS Gets a Spark – The Motley Fool
- Can This Stock Go Higher? – The Motley Fool
- 5 Stocks Making Cash – The Motley Fool
- CNBC's biotech guru Mike Huckman pointing out – Blog at The Motley Fool
- Baby boomers get ready to be able to Tap a better ED Drug. – Blog at The Motley Fool
- A Big Upgrade for Sanofi-Aventis – The Motley Fool
- 4-Star Stocks Poised to Pop: Alkermes – The Motley Fool
- UPDATE: Icahn Reports New Stakes In Genzyme, Forest Labs – SmartMoney
- Music to Health-Care Investors' Ears – The Motley Fool
- Proposed AstraZeneca Anticlotting Drug Better Than Plavix:Study – SmartMoney
- Questioning Pfizer's Integrity – The Motley Fool
- UPDATE 1-Lilly snags AstraZeneca executive as new R&D head – Reuters
- AstraZeneca Research Chief Lundberg To Join Eli Lilly – SmartMoney
RSS Headlines
Fool UK
